CSIMarket
 
Inozyme Pharma Inc   (INZY)
Other Ticker:  
 
 
Price: $6.0000 $0.11 1.868%
Day's High: $6.24 Week Perf: 4.9 %
Day's Low: $ 5.78 30 Day Perf: 5.08 %
Volume (M): 698 52 Wk High: $ 7.33
Volume (M$): $ 4,187 52 Wk Avg: $4.91
Open: $5.94 52 Wk Low: $2.59



 Market Capitalization (Millions $) 341
 Shares Outstanding (Millions) 57
 Employees 56
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -68
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Inozyme Pharma Inc
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for rare and debilitating disorders of the calcification and mineralization processes. The company was founded in 2015 by a team of experienced biotech executives and is headquartered in Cambridge, Massachusetts.

Inozyme Pharma is dedicated to developing therapeutic solutions for patients targeted with rare, life-threatening diseases. The so-called ecalcifying disorderse Inozyme is working to tackle are characterized by abnormal mineral deposits in soft tissues, joints and organs, causing severe morbidity and often death.

The leading focus of Inozymees pipeline is the development of enzyme therapies that have the potential to safely and effectively restore a normal balance of mineral, calcium, and phosphate homeostasis.

Its leading therapy, INZ-701, is an enzyme replacement therapy designed to treat hypophosphatasia (HPP) and has already been granted orphan drug designation by the FDA in the US and the EMA in Europe, for both infantile and juvenile forms of HPP. HPP is a rare genetic disorder characterized by the abnormal mineralization of bones and teeth. In infants, the disease is lethal if not treated within the first year of life, and can result in a delayed ability to walk and bone fractures in older children and adults.

Inozymees pipeline also includes INZ-801, a therapy that is aimed at treating ENPP1 deficiency disorder, a rare, inherited disorder that results in calcification problems of the joints and arteries. Inozyme has another preclinical program in development for Generalized Arterial Calcification of Infancy, another rare genetic disorder characterized by abnormal calcifications in the blood vessels.

The company has an experienced leadership team with a proven track record in the biotech industry. Its board of directors includes leaders in finance and healthcare and boasts extensive experience in developing new therapies at the leading pharmaceutical and biotech companies.

Inozyme Pharma is backed by leading institutional investors including Novo Ventures, Morningside Ventures, RA Capital Management, and Longitude Capital. The company has successfully raised over $126 million in funding since inception to advance its pipeline development.

Overall, Inozyme is a biopharmaceutical company with a powerful mission and a clear focus on developing therapeutic solutions to life-threatening rare diseases. The company has a dedicated leadership team, strong institutional support, and an innovative pipeline of enzyme replacement therapies that have the potential to change the standard of care for patients with calcifying disorders.


   Company Address: 321 Summer Street Boston 2210 MA
   Company Phone Number: 330-4340   Stock Exchange / Ticker: NASDAQ INZY
   INZY is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Inozyme Pharma Grants Stock Options to New Employees, Demonstrating Company Confidence and Enhancing Shareholder Value

Published Tue, Feb 6 2024 1:31 PM UTC



Inozyme Pharma Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company focusing on innovative therapeutics for pathologic mineralization and intimal proliferation, recently announced the granting of stock options to four new employees. Aligned with the Company's 2023 Inducement Stock Incentive Plan, these options serve as an inducement for the ...

Inozyme Pharma Inc

Inozyme Pharma Inc Reports Operating Loss of $18.1 Million, Raising Eyebrows in the July-September 2023 Quarter

Inozyme Pharma Inc, a pharmaceutical company, has seen a significant increase in its shares over the past five trading days. The shares have recorded a solid gain of 8.53% during this period. Looking at the bigger picture, the shares are up by an impressive 144.62% in the year 2023.
Currently, Inozyme Pharma Inc shares are trading on the NASDAQ, and they are 19.4% below their 52-week average. This may worry some investors, but it's important to understand the context of the company's financial situation.

Inozyme Pharma Inc

Inozyme Pharma Inc Faces Financial Struggles in Q2 2023: Are Revenue Woes a Cause for Concern?

As the reporting cycle for the April to June 2023 period continues, a number of entities within the Major Pharmaceutical Preparations sector have released their financial numbers. One such company that has caught the attention of analysts is INZY, which has reported an operating shortfall of $-16.394 million for the mentioned period. This represents a worsening of the operating shortfall compared to the second quarter of 2022, where it stood at $-15.391 million.
The deteriorating financial performance of INZY has sparked speculation among analysts regarding the company's ability to generate revenue. It is not uncommon for companies in the pharmaceutical industry to experience rough patches as they strive to establish a profitable business model. The second quarter of 2023 appears to be one such challenging period for INZY, as the operating shortfalls have widened to $-15.583 million.

Inozyme Pharma Inc

Inozyme Pharma Inc Defies Industry Expectations with $-18.369 Million Deficit, Garnering Investor Attention

The Major Pharmaceutical Preparations sector is typically dominated by well-established businesses that are closely followed by investors and analysts. However, some up-and-coming companies in the industry are beginning to gain attention due to their potential for growth and innovation.
One of these companies is Inozyme Pharma Inc, which recently reported an operating deficit of $-18.369 million for the first quarter of 2023. While the company has not yet disclosed its revenue for the quarter, this figure provides insight into the company's financial performance and prospects for the future.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com